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Abstract
The twin processes of viral evolutionary escape and reversion in response to host immune pressure,
in particular the cytotoxic T-lymphocyte (CTL) response, shape Human Immunodeficiency Virus-1
sequence evolution in infected host populations. The tempo of CTL escape and reversion is known
to differ between CTL escape variants in a given host population. Here, we ask: are rates of
escape and reversion comparable across infected host populations? For three cohorts taken from
three continents, we estimate escape and reversion rates at 23 escape sites in optimally defined Gag
epitopes. We find consistent escape rate estimates across the examined cohorts. Reversion rates are
also consistent between a Canadian and South African infected host population. Certain Gag escape
variants that incur a large replicative fitness cost are known to revert rapidly upon transmission.
However, the relationship between escape/reversion rates and viral replicative capacity across a
large number of epitopes has not been interrogated. We investigate this relationship by examining
in vitro replicative capacities of viral sequences with minimal variation: point escape mutants
induced in a lab strain. Remarkably, despite the complexities of epistatic effects exemplified by
pathways to escape in famous epitopes, and the diversity of both hosts and viruses, CTL escape
mutants which escape rapidly tend to be those with the highest replicative capacity when applied as
a single point mutation. Similarly, mutants inducing the greatest costs to viral replicative capacity
tend to revert more quickly. These data suggest that escape rates in gag are consistent across
host populations, and that in general these rates are dominated by site specific effects upon viral
replicative capacity.
Keywords: HIV-1, escape, CTL, phylodynamics, epistasis
Abbreviations: HIV-1, Human Immunodeficiency Virus-1; CTL, Cytotoxic T-lymphocyte, MCMC;
Markov Chain Monte-Carlo
In HIV-1 infected individuals there is a constant arms race between the virus on one side and the
host immune response on the other [1–3]. The cytotoxic T-lymphocyte (CTL) response - a part of the
adaptive immune system - is a major driving force of HIV evolution both within and across infected
individuals [4, 5]. Within nucleated cells, cytosolic peptides (both self and non-self) are presented at
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the cell surface by human leukocyte antigen (HLA) class I molecules [6], encoded by HLA genes; the
most variable loci in the entire human genome [7]. These protein fragments are known as ‘epitopes’
upon presentation. CTLs may then recognise epitopes as non-self and destroy the presenting cell. The
CTL response can select for mutations within or flanking epitopes which result in reduced immune
recognition of virally infected cells. These variants, termed CTL escape mutants, may reduce HLA class
I binding affinity, alter epitope processing, or affect T-cell receptor contact sites [8–11]. Importantly,
the repertoire of viral epitopes that may be presented is dependent upon the ‘type’ of the HLA class I
molecule. If an epitope can be presented, it is said to be ‘restricted’ by that HLA type, and the host
is known as ‘HLA matched’ for that epitope. A host lacking the class I molecule required to present
the epitope is known as ‘HLA mismatched’ for that epitope. Viruses bearing escape mutations can
be transmitted between hosts [12, 13], and reversion of the infecting virus may take place due to the
removal of HLA dependent selection pressure and viral fitness costs of CTL escape mutants [14–17].
The viral population present in a given infected individual reflects the selective environment of the
current host as well as the remnants of selection from previous hosts. During the course of HIV-
1 infection, viral mutations can open pathways to CTL immune escape or compensate for costs to
replicative capacity of such mutations [18–22], which can lead to a delay in reversion upon subsequent
transmission [20]. Methods used to model and parameterise the CTL escape and subsequent reversion
often assume that the timings of escape and reversion are governed by behaviour at a single site
[23–30]. This is a clear simplification. The existence and potential complexity of epistatic interactions,
coupled with the diversity in HLA profiles, CTL killing efficiency, drug regimes, and vertical T-cell
immunodominance [31] leads to the following questions: can individual escape mutants be characterised
as having their own escape and reversion rates in a given infected host population, and are escape and
reversion rates consistent across host populations?
The ideal data to answer these questions would consist of longitudinal viral sequence samples starting
early in infection from a large number of hosts with known HLA types. However, this is not feasible.
Instead, we have developed a method which allows us to use cross-sectional viral sequence data and
host HLA information to estimate escape and reversion rates whilst accounting for the underlying
viral genealogy [24]. This allows us to estimate population specific rates of escape and reversion at
escape sites within optimally defined [32] epitopes. By comparing the resultant escape/reversion rate
estimates, we can test their consistency between infected host populations.
We apply our model to gag sequence data taken from three cohorts sampled from three continents:
HOMER (British Columbia, Canada) [33], SSITT (Switzerland) [14, 34], and Bloemfontein (Bloem-
fontein, South Africa) [35, 36]. We find agreement between escape rate estimates, with the strongest
positive correlation observed between CTL immune escape estimates across cohorts. Escape rate es-
timates are consistent between viral populations with distinct HIV-1 subtypes, where gag sequence
divergence is as high as ∼ 9.2%. We also find consistent reversion rate estimates for the Bloemfontein
and HOMER datasets (distinct HIV-1 subtypes, average nucleotide sequence divergence: 8.9%). Given
the potential collection of paths through sequence space which could restore replicative fitness for a
given escape variant, we find it particularly surprising to observe such a highly significant association
between reversion rate estimates. These results suggest that given information regarding the dynamics
of escape and reversion in one region, we may begin to make valid statements about these rate pro-
cesses in other parts of the world, even when viral populations and HLA frequencies are substantially
different. Our results support the findings in [37], in which escape pathways are found to be broadly
similar even across viral subtypes, and align with fitness effects in Pol observed by Hinkley et al. [38]
which demonstrate that whilst HIV-1 protease and reverse transcriptase is ‘characterised by strong
epistasis’, a large portion of predictive power of replicative capacity is through single locus effects. To
determine the extent of single locus effects on viral escape/reversion rates, we turn to data gathered
from in vitro assessments of viral replicative capacity [39]. These estimates use site directed mutage-
nesis to induce escape variants in an otherwise conserved viral background, so do not reflect epistatic
interactions in pathways to escape. We ask: do we observe correlations between our population derived
escape or reversion rates, and these in vitro replicative capacity estimates? The emergence of a new
consensus viral sequence within a given host is determined by the balance between immune escape
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and replicative fitness cost within that host’s immunological background [1, 40–43]. Naively ignoring
all epistatic interactions, viral diversity, and assuming that all CTL escapes are equally beneficial to
the virus, we would expect an escape mutation which incurs a small cost to viral replicative capacity
to rapidly fix in the host’s viral population. Similarly, an escape mutant which dramatically reduces
replicative capacity would be expected to take far longer to reach intra-host consensus (we may make
similar intuitive statements regarding reversion). Remarkably, despite these vast simplifying assump-
tions informing this intuition, we find a significant positive correlation between our SSITT escape rate
estimates and in vitro replicative capacity, and a significant negative correlation between our HOMER
reversion rate estimates and in vitro replicative capacity. We find it surprising to see such correlations
between rate estimates measured in a reductionist, in vitro replicative capacity assay and a real world
population of diverse individuals sharing diverse viruses. We conclude that whatever epistatic effects
may be present across the HIV-1 proteome, in general rates of escape and reversion are largely dictated
by the costs and benefits of individual mutations.
Methods
Cohorts
We consider paired viral sequence and host HLA type data taken from studies carried out in three
populations: Switzerland (Swiss portion of the Swiss-Spanish intermittent treatment trial (SSITT)
cohort [14, 34]); British Columbia, Canada (HAART observational medical evaluation and research
(HOMER) cohort [33]); and Bloemfontein, South Africa [35, 36]. For each dataset bulk sequencing
data was available, in which sequences obtained are assumed to represent the intra-host viral consensus
sequence. We briefly outline the studies and portions of datasets used in Table 1. For each dataset, we
restrict our attention to gag and to the subset of sequences with the majority subtype in each population
as assessed using RIP [44]: subtype B for SSITT and HOMER, and subtype C for Bloemfontein. Our
reasons are threefold. Firstly, non-synonymous mutations in gag are likely to have a detrimental
fitness effect as they encode structural proteins that are among the most highly conserved in the
viral proteome [45]. Indeed, variants in gag can result in a measurable reduction in viral replicative
capacity, as estimated by a variety of methods [39, 46–49]. Secondly, the most protective HLA alleles
are associated with CTL responses to Gag proteins [50–52]. Finally, site directed mutagenesis followed
by replicative capacity assays have been carried out for a large number of known escape variants located
in the gag gene [39].
Due to issues of confidentiality, we were unable to obtain the year of sequencing for the analysed portion
of the HOMER dataset [33]. However, this is not required as we do not require a rescaling to calendar
time (measured in years) from substitutions site−1 to determine the existence of rank correlations of
rate estimates across datasets. The 184 viral sequences which we analyse from HOMER dataset are
taken from the year between 1996 and 1999 inclusive in which the largest number of gag sequences
were obtained. For the SSITT dataset, separate collections of sequences were available for sequences
encoding the p17 and p24 proteins in the gag gene. There was not a strong overlap between the
patient identifiers of these two sequence sets, so we chose to analyse the two viral sequence regions
independently.
Estimating escape and reversion rates
We estimate HLA prevalence using data from the HLA FactsBook [54]. For the Canadian (HOMER)
and Swiss (SSITT) datasets, we set the prevalence at the ‘Caucasian’ estimate. For the African data
(Bloemfontein, and the collection of cohorts summarised in Table S1), we set the prevalence at the
‘Black’ estimate. Epitopes examined by Boutwell et al. represent all optimally defined CTL epitopes
at the time of publication [32]. Escape mutations within these epitopes were defined based upon a list
of HLA-associated HIV polymorphisms identified via statistical association [22, 55]. We define escape
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Dataset SSITT [14,34] HOMER [53] Bloemfontein [35,36]
Population analysed Switzerland British Columbia, Canada Bloemfontein, South Africa
Cohort size n = 133
Zürich (n = 29), Geneva (n = 26),
Bern (n = 11), Basel (n = 11)
St Gall (n = 8), Lugano (n = 7)
Lausanne (n = 5)
n = 567 n = 884,
plasma taken from n = 278
Sampling date 2000 Between 1996 and 1999 February - September 2006
Sequences analysed p17 n = 38, p24 n = 55 n = 184 n = 198
Treatment HAART ART naive on recruitment,
initiated HAART between
August 1996 and September 1999
ART naive
Study requirements Undetectable VL for >6 months,
CD4+ count > 300µl−1.
no history of non-nucleoside
reverse transcriptase inhibitors
≥ 3 antiretroviral drugs Chronic, plasma taken by
CD4+ count,
low and high favoured:
96 high (> 500µl−1),
18 medium (200− 400µl−1),
164 low (< 100µl−1)
Table 1: Summary of three studies from which gag sequence data was available. For the SSITT
and Bloemfontein datasets the number of sequences analysed is lower than the cohort size through a
combination of lack of sequencing of gag, and data cleaning. For the HOMER dataset, the number of
sequences analysed is lower than the cohort size due to restriction of the analysis to a single (unknown)
calendar year, and data cleaning.
as any amino acid changes which occur at the same position as escape mutations provided in Boutwell
et al. [39]. This is clearly an imperfect definition, but provides a sensible compromise between the
clear overestimation of allowing all mutations within an epitope to be defined as escape, and only
considering exact mutations validated as escapes in vitro [23]. In both of the approaches that we
describe, it is important to note that estimates of escape represent averages across hosts known to
restrict the epitope, and do not condition on the host making a CTL response or driving an escape
during the course of infection. We are thus implicitly incorporating a scaling - the probability that an
epitope is targetted conditional on the individual being HLA matched, which may vary across epitopes.
Maximum a posteriori (MAP) estimate using our integrated method
Full details of the method are provided in Palmer et al. [24]. Briefly, we combine Felsenstein’s tree
peeling algorithm with existing phylogenetic software to merge statistical phylogenetic techniques with
an ordinary differential equation (ODE) model which captures the processes of transmission, escape,
and reversion. By doing so, we are able to use the information contained within the viral genealogy
to infer estimates of escape and reversion rates (λesc, λrev). There are four key steps in our inference
regime:
1. Make the mild assumption that the genealogy and HLA/escape information are conditionally
independent given the viral sequence information with the epitope removed.
2. We perform Markov chain Monte Carlo (MCMC) to sample genealogies from the posterior condi-
tional on the viral sequence data with the epitope removed using BEAST [56]. We use a coalescent
prior in an exponentially growing infected host population. The growth rate parameter of the
infected population is sampled within the MCMC.
3. For each sampled viral genealogy, we determine the posterior density for (λesc, λrev). This is
achieved through a modification of Felsenstein’s peeling algorithm [57]. Further details of this
step can be found in the Supplementary Methods.
4. By averaging over tree specific posteriors, we obtain a consensus posterior density for (λesc, λrev).
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Purely ODE based, naive model
To analyse a particularly large fourth dataset for which rate estimation under our integrated model is
not computationally feasible, we turn to a simpler compartment based ordinary differential equation
(ODE) model of Fryer et al.. For each escape variant under consideration, viral sequence/HLA genotype
pairs are split into four classes: HLA mismatched without escape, HLA mismatched with escape, HLA
matched without escape and HLA matched with escape. Given these four proportions for an escape
site, we then determine a best fit for λesc and λrev under the model described in Fryer et al. [23] during
the exponential growth phase of the epidemic (Equations (1) - (4) in the Supplementary methods).
Best estimates are determined using BFGS [58], an approximation to Newton’s method of hill climbing.
Time of the start of the epidemic is set at the time to the most recent common ancestor of a BEAST
run on the gag sequence data for each dataset.
Estimates of time to escape/reversion could not be obtained when no individuals in the cohort pos-
sessed the restricting HLA. When an escape mutation residing in an epitope reaches consensus in the
population, the variant peptide is known as a negatope [53, 59]. Negatopes of HIV-1 subtype B as
reported in Boutwell et al. [39] are highlighted in Tables S2 - S4 by asterisks.
In vitro viral replicative capacity
In Boutwell et al. [39], the fitness cost of an escape variant is approximated by determining the in
vitro replicative capacity of the escape mutant inserted into a subtype B lab strain, in the absence
of any other sequence variation. The measure of fitness is essentially the exponential in vitro growth
rate of an isolate relative to the lab strain. Full details of the procedure are provided in [39]. We use
these published replicative capacity assay measurements for 23 gag escape variants where both viral
sequence data and the relevant HLA locus information was available in all three cohorts.
Accounting for multiple testing
To account for multiple testing for each collection of tests of association, we perform permutation tests
by shuffling the labellings of escape variants and re-evalaute correlation coefficients 100,000 times. This
allows us to estimate the probability of observing a collection of Spearman rank correlation coefficients
at least as extreme as those observed in the data. In all cases we obtain significant p-values. In each
section, we also report the pairwise correlation coefficients, and describe a correlation as significant if
its associated p-value is below 0.05.
Results
We apply our integrated model [24], and purely ODE based model [23] to data from the SSITT,
HOMER and Bloemfontein cohorts. Detailed results, together with estimated replicative capacity of
escape variants as previously estimated by an in vitro assay [39] are shown in Tables S2, S3 and S4
for the HOMER, SSITT and Bloemfontein datasets respectively. Figure S1 summarises the prevalence
of escape in all three regions. For each escape site we determine the proportion of HLA matched
hosts harbouring the viral escape form. We perform the same calculation for HLA mismatched hosts.
These two values for each of the 23 escape sites are then plotted against each other. The majority of
the points lie below y = x, suggesting that selection for escape is taking place in the majority of the
HLA/epitope pairings.
Estimates of time to escape and time to reversion for the HOMER dataset are given in units of substitu-
tions site−1. This is because the date of sampling was not available due to issues of confidentiality, and
thus a scaling from substitutions site−1 to years could not be estimated using BEAST [60]. Throughout
our results, we report the Spearman rank correlation coefficient. We choose this statistic as variance
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Figure 1: Comparing estimated times to escape/reversion in each pair of cohorts. Figures 1A
- 1C show MAP estimates of time to escape for the SSITT vs. HOMER, Bloemfontein vs. SSITT and
Bloemfontein vs. HOMER MAP estimates respectively. Figures 1D - 1F show the corresponding MAP
estimates of times to reversion. Numbers following a dash refer to the ordering in Tables S2 - S4, as
some epitopes have more than one escape mutation and/or associated restricting HLA. Negatopes are
highlighted in red for time to escape. The scale bar indicates the HLA prevalence taken from the HLA
handbook [54] for each of the restricting HLA types associated to escape in Caucasian populations.
y = x is plotted in solid grey where estimates are on the same timescale. Dotted grey lines represent
an estimate of y = x after a change of timescale assuming the Swiss and Canadian epidemics are
expanding at roughly the same rate.
in rate estimates increases drastically as the true underlying rates tend to infinity (or zero if we use
a log scale). Also, when comparing replicative capacity to rate of escape or reversion, it is unclear a
priori that any such relationship would be linear. In each plot, epitopes are abbreviated by writing the
first amino acid of the epitope, followed by last, followed by the epitope length (e.g KRWIILGLNK →
KK10).
Are rates of escape and reversion consistent across infected populations in different
parts of the world?
Escape rates
Figure 1A-1C shows scatter-plots of estimates of average time to escape for the different combina-
tions of populations: HOMER vs. SSITT, HOMER vs. Bloemfontein, and SSITT vs. Bloemfontein
respectively. We find strong positive correlations between escape rate estimates for the SSITT and
HOMER cohorts (ρ = 0.825; p = 0.00000675). We do not find clustering of restricting HLAs of similar
prevalence in any portion of the space of times to escape suggesting that the observed correlation is
6
not an artefact of the HLA prevalence in the two populations. We also observe significant positive
correlations between estimates of average time to escape for the remaining population combinations in
which HIV-1 subtypes are distinct (analysed SSITT and HOMER viral sequences are subtype B, anal-
ysed Bloemfontein viral sequences are subtype C): HOMER vs. Bloemfontein: ρ = 0.538; p = 0.0169,
and SSITT vs. Bloemfontein: ρ = 0.614; p = 0.00570. These results suggest that escape rates are
comparable across infected host populations. Under a permutation test (see Methods) we find that
the results are significant, p < 0.00001.
In determining the strength of positive correlation between escape rate estimates across populations, we
note that a potential source of bias is the inclusion of negatopes: any mutation at high prevalence across
hosts will result in a high escape rate estimate, and consequently may lead to spurious associations.
To determine if this is the case in our data we remove negatopes (highlighted in red in Figure 1), and
re-evaluate correlation coefficients and p-values. All positive correlations remained significant after
removal of negatopes (HOMER vs. SSITT: ρ = 0.779; p = 0.000189, HOMER vs. Bloemfontein:
ρ = 0.549; p = 0.0276, and SSITT vs. Bloemfontein: ρ = 0.657; p = 0.00730). The p-value for the
permutation test to account for multiple testing also remained significant, p = 0.0006.
We sought to validate our findings with further data. A potential source of error in our Bloemfontein
escape rate estimates was the low number of individuals in the Bloemfontein dataset with the restricting
HLA (shown in Table S3), due to the rarity of these HLA genotypes in African populations coupled
with the limited size of the dataset. Additionally, some escape mutations are found at 100% prevalence
or are not present at all in the Bloemfontein dataset. 9/20 rate estimates are obtained from data for
which just one individual has the restricting HLA, or 0%/100% of HLA matched hosts have the escape
mutation. Such escape proportions in HLA matched hosts result in a lack of power to estimate escape
rates and can lead to spurious rate estimates [24] (they may lead to estimates of ∼ instantaneous escape
or ∼ infinite time to escape). To attempt to correct for this source of error we obtained a far larger
dataset of African sequences coupled with host HLA genotype data [35, 61–67]. Unfortunately, such
a large dataset was computationally intractable using our integrated model. We therefore turn to the
simpler ODE model of Fryer et al., noting the agreement between escape rate estimates derived with
our integrated method and this compartment based ODE approach [24], see Table S5 and Palmer et
al [24]. The large dataset summarised in Table S1 is not a single study in a single homogeneous mixing
population. Nevertheless, we apply the ODE method to all of the data in Table S1. Scatter-plots
of estimates of time to escape using the naive ODE method on the large African dataset against the
two HIV-1 subtype B datasets are shown in Figures S3. In both cases we find significant positive
correlations (ρ = 0.711, p = 0.000963 and ρ = 0.765; p = 0.000175 for African against HOMER
and African against SSITT time to escape estimates respectively) which remained significant after
removal of negatopes (African vs. HOMER ρ = 0.723; p = 0.00240, African vs. SSITT ρ = 0.819;
p = 0.000170). We also note that the strongest disagreement seen in the plots occurs when time to
escape is very low in one or other of the populations. This occurs when the escape mutation is at high
prevalence in one or other of the populations, possibly as a result of founder effects.
Reversion rates
Figures 1D-1F and S4 show the corresponding scatter-plots of estimates of time to reversion. We
find a significant agreement between the rank ordering of HOMER and Bloemfontein reversion rate
estimates (ρ = 0.715, p = 0.00129). This correlation was not repeated in any of the other combination
of the analysed cohorts. However, the collection of correlation coefficients observed are significant
under a permutation test, p = 0.0011. We note that TLYCVHQR, [A]ISPRTLNAW, DRFYKTLRA,
KRWIILGLNK, and KRWIILGLNK are estimated to have extremely low reversion rates when using
the SSITT data. This is potentially due to the small SSITT cohort size and the inherent difficulty in
estimating reversion rates when the restricting HLA type is rare and/or the true underlying reversion
rate is low (see simulation studies in [24]). Further data is required to validate these rate estimates.
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Sequence divergence within and between cohorts
The consistency between escape rate estimates in three different populations seems to suggest that
the viral background on which an escape, or pathway to escape is placed is generally a secondary
effect during CTL immune evasion. If it weren’t, then we would be expect such effects to mask
positive correlations between escape rate estimates across host populations. To investigate the extent
of viral divergence between the examined datasets, we determined nucleotide and amino acid sequence
divergence as measured by Hamming distance (Figure S7). We evaluate this metric for the region of
gag over which we had the largest number of available sequences. This was to avoid biasing through
differences in sequence diversity across gag. A neighbour joining tree using the K81 model [68] is shown
in Figure S8. Taken together, Figures S7 and S8 show a dramatic divergence between the subtype B
and C sequences, as we would expect. We observe mixing of lineages between Canada and Switzerland,
coupled with examples of cohort specific clades.
The consistent and significant positive association between escape rate estimates exists despite a mean
divergence of up to 9.2% between viral sequence datasets.
Escape and reversion rates within cohorts vs. in vitro replicative capacity estimates
To examine the importance of single escape variants upon rates of escape and reversion, we consider
the most extreme case: complete removal of all sequence variation except at the site of the escape
variant. We compare in vitro replicative capacity of site directed mutants with our escape and reversion
estimates. For a collection of 23 epitope variants we had access to sequence data and an estimate of
replicative fitness cost from Boutwell et al., in which site directed mutagenesis was applied to a subtype
B lab strain. If we naively assume an absence of epistasis and that the benefit of evading CTL mediated
immunity is equal for all escape variants, then we would expect to see average time to escape negatively
correlated with in vitro replicative capacity, and average time to reversion positively correlated with
in vitro replicative capacity.
Subtype B: Escape and reversion rate estimates in SSITT and HOMER datasets vs. in
vitro replicative capacity estimates
We first examine the correlation between this in vitro measure of replicative capacity and rate estimates
in the two populations in which subtype B is the predominant subtype. Results are displayed in
Figure 2 (permutation test p-value to account for multiple testing of escape rate versus replicative
fitness; p = 0.00192, corresponding p-value for reversion; p = 0.0113). Surprisingly, despite these
naive assumptions we indeed observe a negative correlation between time to escape and replicative
capacity for the Spearman rank correlation coefficients which reaches significance for the SSITT data
(ρ = −0.451, p = 0.0231). We also observe a positive correlation between time to reversion and
replicative capacity which reaches significance for the HOMER data (ρ = 0.530, p = 0.00815). These
findings again suggest that epistatic effects are generally secondary to either the benefits to the virus of
CTL escape in HLA matched hosts, or the detriment to viral replicative capacity in HLA mismatched
hosts. Such effects appear to be overwhelmed by the impact of insertion or removal of escape mutants.
Logically, if epistasis dramatically affected the available pathways to escape/reversion then we would
not expect to see time to escape or reversion correlate (negatively and positively respectively) with viral
replicative capacity experiments which discard all sequence variation aside from the escape mutant.
Finally, we note that outliers in Figure 2C are exactly those discussed in the previous section. Again
we emphasise that larger European sequence datasets with host HLA information should be analysed
to determine the accuracy of the reversion rate estimates for these outliers.
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Figure 2: Replicative capacity plotted against the MAP estimates of time to escape and
reversion. The first and second columns display estimates obtained using in vivo data from Switzer-
land (SSITT) and Canada (HOMER) respectively. Numbers after the epitope abbreviation refer to the
ordering in Tables S2 - S4, as some epitopes have more than one escape mutation and/or associated re-
stricting HLA. Time to escape is measured in years except in the case of the HOMER cohort in which
it is measured in units of substitutions. Spearman rank correlation coefficients; ρ, with associated
p-values are displayed on each plot.
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Figure 3: Summary of all associations. Spearman rank correlations between expected time to
escape across cohorts and with in vitro replicative capacity are shown above the leading diagonal.
Spearman rank correlations between reversion rates across cohorts and with in vitro replicative ca-
pacity are shown below the leading diagonal. Spearman rank correlation coefficients with p < 0.05
are highlighted with a black square. Associated Spearman rank correlation coefficients are coloured
according to the colourbar.
Subtype C: Escape and reversion rate estimates in the Bloemfontein dataset vs. in vitro
replicative capacity estimates
We next sought to determine if this correlation was replicated in the Bloemfontein dataset where sub-
type C predominates. We do not find any such correlation between estimated time to escape/reversion
in Bloemfontein (or the full African dataset using the naive ODE method, see Figure S6) and in vitro
replicative capacity. We note that the permutation test p-value remains significant after accounting
for these further comparisons, p = 0.0113.
Discussion
There is a large literature detailing the existence and complexity of pathways to escape, compensatory
mutations and other forms of epistasis in HIV-1 [4, 21, 22, 38, 43, 69–73]. Given this complexity, it is
unclear whether the processes of CTL immune escape and reversion can be meaningfully represented
by describing each escape variants rate of escape and reversion. In this work, we sought to determine
if it makes sense to characterise an escape variants with an escape and reversion rate, and ask if
such rate estimates are consistent across host populations. We found significant consistency between
expected time to escape for each cohort combination, even across HIV-1 subtypes where average
sequence divergence between viral populations was as high as ∼ 9.2%. Consistency in escape/reversion
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rate estimates across populations lead to the following question: is the fitness effect at a single locus
a predictor of the tempo of viral escape or reversion? To test this, we considered estimates of in
vitro replicative capacity applied to a subtype B lab strain [39]. If we naively assume that all escape
mutations have the same impact upon CTL immune evasion, then we would expect CTL escape
mutations that are more costly in vitro (i.e. that have a lower viral replicative capacity) to escape
more slowly in HLA matched hosts and revert more rapidly in HLA mismatched hosts. The use of in
vitro replicative capacity of single escape variants applied to a lab strain as a measure of its fitness
averaged over an entire infected population is clearly a vast simplification. Our method also requires
a number of simplifying assumptions [24]. Despite this, as expected, we find a significant negative
correlation between in vitro replicative capacity and estimated time to escape in the Swiss dataset
(SSITT), and a significant positive correlation in vitro replicative capacity and in vivo estimates of
time until reversion in the HOMER dataset. For the Bloemfontein dataset (consisting of subtype C
HIV-1 sequences), no association was found for either escape or reversion estimates. This could suggest
a role for epistatic interactions, potentially involving sites distinguishing subtypes B and C. However,
we note that the similar replicative capacity of measured escape variants and the noise of such assays,
coupled with our low power to estimate many of these rates given the rarity of the associated HLA
types in African populations could also lead to a loss of signal of association. Furthermore, founder
effects and overlapping epitopes associated to other HLA types have the potential to affect our rate
estimates.
Shannon entropy [74] obtained from viral sequences taken across infected hosts has been used as a
surrogate measure of the replicative fitness cost of CTL escape [31] as it provides a metric for the
variability at a given site. Authors thus assume that a site of lower variability will escape more slowly.
However, whilst useful, this simple metric ignores the relative prevalence of HLA types in the host
population, the dependency structure inherent in the viral genealogy, and has no notion of ‘escape’
in its calculation. By using a simple model of escape and reversion across infected hosts to pick
apart the relative contributions to variation observed at escape sites we obtain biologically meaningful
parameters which correlate with replicative fitness as we would (perhaps naively) expect. For all of
our analysed datasets, Shannon entropy does not correlate with viral replicative capacity (ρ = 0.193;
p = 0.208, ρ = 0.0226; p = 0.462, ρ = 0.0850; p = 0.361, for the SSITT, HOMER, and Bloemfontein
cohorts respectively).
During the process of escape, it appears that epistatic effects are often overpowered by the effect of
a single point mutation; giving rise to consistent escape rate estimates across host populations. This
result is powerful as it allows us to inform a null hypothesis when studying a new HIV-1 dataset. Evi-
dence for correlation between reversion rate estimates across populations and with in vitro replicative
capacity is less clear cut. This may be due to the inherent difficulty in estimating reversion rates.
Indeed, there is contradiction in the literature regarding the rate of reversion. A few famous epitopes
consistently revert in the absence of HLA pressure [15,20,31,62]. However, whether this readily extends
across escape variants is a subject of debate. Some cohort studies have suggested little evidence for
reversion [5, 31, 75], and cross-sectional estimates suggest a low rate of reversion on average [23, 24].
However, a large longitudinal study [76], transmission pair data [77] and separate cohort studies [45],
have suggested that reversion occurs early and is widespread. Other studies have concluded that be-
tween 20% and 30% of non-synonymous substitutions within host constitute reversions [45,78,79]. Such
estimates depend on the authors’ definition of reversion, and highlight the need for data sharing (both
host HLA and viral sequence data) to critically compare methodologies, increase statistical power to
inform estimates and increase our understanding of the underlying biology.
Under our cross-sectional model, reliable reversion rate estimation requires multiple instances of trans-
mission of escape mutations followed by reversion in an HLA mismatched host, an event which occurs
less often than transmission of wildtype at the site(s) under consideration (particularly if the restrict-
ing HLA is rare, or the escape rate is relatively low). Indeed, simulation studies show that a lack of
data and low underlying reversion rates can lead to dramatic underestimation of the true rate [24].
Despite this, we observe a strong signal of association between the reversion rates estimated using the
Bloemfontein data and those estimated using the HOMER dataset. An alternative explanation for the
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lack of a signal of correlation in reversion rate estimates between cohorts is that epistatic effects are
important in a subset of the analysed epitopes. Epistatic effects playing a stronger role in the reversion
process does make sense intuitively: on average a viral lineage spends a longer period of time within
HLA mismatched hosts (because HLA diversity is so high). Selection to increase replicative capacity
acts across the entirety of the viral genome both in the presence and absence of any HLA associated
immune pressure (contrast this to CTL associated selective pressure, which is strongest in and around
epitopes). The high dimensionality of sequence space would then lead us to expect multiple pathways
to a restoration of viral fitness, not all of which may be associated to a simple reversion of the purported
escape mutation - particularly if the ‘survival of the flattest’ hypothesis is borne out in reality [80].
This study has a number of limitations. Throughout we have applied our methods to subtype B and C
viral sequence data from Canada, Switzerland, South Africa, Malawi and Botswana. Access to further
host HLA information coupled with cross-sectional HIV-1 sequence data would allow us to determine
if similar orderings of escape and reversion rates are observed in further infected host populations,
potentially harboring viruses with other HIV-1 subtypes. This will be particularly interesting given the
dissimilar escape pathways found by Avila-Rios et al when analysing a collection of subtype B sequences
sampled from Mexico [71], and the significant number of further unique HLA associated amino acid
variants in other viral subtypes and circulating recombinant forms across the globe [81]. The escape
variants analysed here are all found in gag. It would therefore be interesting to determine whether our
results may be extended to other portions of the HIV-1 genome. Reliably interpreting the effect of
replicative capacity on escape and reversion rates in less conserved regions will be difficult. Although
replicative fitness assays are improving all the time [39, 46–48], obtaining the required sensitivity to
distinguish between small differences in replicative capacity associated to variants in less conserved
regions of the viral genome is no easy task. For example, small replicative fitness costs known reverting
mutations can often not be distinguished [43]. The majority of the collection of optimal epitopes studied
[32] have been determined using data from European and North American populations, and thus
associated HLA types are likely to be found at high or moderate frequencies within these populations.
However, differences in HLA allele frequency distributions across the world often makes rate estimation
using data taken from other parts of the world difficult - we sometimes require far larger datasets
to obtain rate estimates for escape variants in one region versus another. Datasets with >∼ 500
sequences in HIV-1 gag become intractable using our integrated method. Ability to incorporate vast
host/virus datasets would allow us to determine escape and reversion rate estimates for escape variants
associated to rare HLA alleles and obtain more accurate estimates for escape mutations associated to
more common alleles whilst accounting for dependency structure inherent in viral sequence data.
Our results are summarised in Figure 3. Escape rates are consistent across three populations in
three different continents and two viral subtypes. We also demonstrate that reversion rates correlate
between estimates obtained from a Canadian and African datasets, though further data are required
to determine if this observation is true in general.
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Supplementary Materials
Supplementary methods: Elaborating on step 3 of our inference regime.
After sampling a genealogy from the posterior output by BEAST, we use the host HLA and escape
information at the tips of the genealogy to determine estimates of (λesc, λrev). Our algorithm is based
on Felsenstein’s tree pruning algorithm [57], where the tip information is of the form (a, b); a, b ∈ {0, 1}
such that {0, 1} in the first entry denotes {HLA mismatch, HLA match}, and {0, 1} in the second entry
denotes {no escape mutation, escape mutation} at the epitope under investigation. Transmission is
assumed to take place at rate λ. The probability that a given individual is HLA matched at the epitope
under investigation is q (assumed to be constant in the population over time, as any selection on hosts
would occur on far larger timescales [82]). We then determine the probability of a given configuration
of the data at the tips, conditional on the genealogy, a collection of epidemiological parameters and
a collection of parameters λ = {λesc, λrev, q}, which model escape and reversion down each lineage
governed by an instantaneous rate matrix Q. The instantaneous rate matrix is based on the following
system of ODEs:
HLA mismatched hosts infected with viruses without escape:
dY 00 (t)
dt
= λ(1− q) (Y 00 (t) + Y 10 (t))+ λrevY 01 (t)− µY 00 (t) (1)
HLA mismatched hosts infected with viruses with escape:
dY 01 (t)
dt
= λ(1− q) (Y 01 (t) + Y 11 (t))− λrevY 01 (t)− µY 01 (t) (2)
HLA matched hosts infected with viruses without escape:
dY 10 (t)
dt
= λq
(
Y 00 (t) + Y
1
0 (t)
)− λescY 10 (t)− µY 10 (t) (3)
HLA matched hosts infected with viruses with escape:
dY 11 (t)
dt
= βcq
(
Y 01 (t) + Y
1
1 (t)
)
+ λescY
1
0 (t)− µY 11 (t) (4)
where λ is the transmission rate. We assume that escape may only occur from the (1, 0) state at
rate λesc and reversion may only occur from the (0, 1) state at rate λrev, as in As in [23, 24]. The
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instantaneous rate matrix Q may then be defined as
Q =

(0, 0) (0, 1) (1, 0) (1, 1)
(0, 0) −λˆ(t)q 0 λˆ(t)q 0
(0, 1) λrev −λrev − λˆ(t)q 0 λˆ(t)q
(1, 0) λˆ(t)(1− q) 0 −λesc − λˆ(t)(1− q) λesc
(1, 1) 0 λˆ(t)(1− q) 0 −λˆ(t)(1− q)
, (5)
where λˆ(t) = λp0(TMRCA − t), with time increasing towards the present. TMRCA is the time before
the present of the most recent common ancestor (MRCA), when t = 0. Qij refers to the transition
from state i to state j. p0(t) is the probability that a lineage at time t in the past does not have any
sampled descendants.
p0(t) = 1− ρ˜(λ− µ)
ρ˜λ+ (λ(1− ρ˜)− µ) exp(−(λ− µ)t) , (6)
where µ is the rate of becoming non-infectious, and ρ˜ is the sampled proportion at the present which we
estimate separately [83]. This extra factor must be included to avoid double counting of transmission
events, as we assume transmission events occur at coalescences within the tree. These internal nodes
are the transmission events which result in a descendant which is sampled at the present, and occur
with probability 1 − p0(TMRCA − t). We wish to determine the probability of a branch beginning in
state i and ending in state j in order to then evaluate the likelihood over the entire tree. If we define
P(t) = (P(0,0)(t), P(0,1)(t), P(1,0)(t), P(1,1)(t)) to be the vector of probabilities of observing each state
at time t, this amounts to numerically evaluating the solution to
P˙(t) = P(t)Q(t) (7)
at the end of each branch within the tree, and subject to a prior on the state at the root, and some
modifications to ensure a transmission at each internal node, full details of the algorithm are provided
in [24].
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Figure S1: Scatter-plot of escape proportions in HLA matched and HLA mismatched hosts,
coloured by population. Data points in which no individuals in a population are HLA matched
(0/0 escape proportion in HLA matched hosts) were excluded. SSITT, Bloemfontein and HOMER
data are shown in red, green and blue respectively. Numbers after the abbreviation of each epitope
refers to the ordering in Tables S2 - S4, as some epitopes have more than one escape mutation and/or
associated restricting HLA.
Escape Reversion
Study ρ p ρ p
SSITT 0.862 0.00000102 0.320 0.0909
HOMER 0.794 0.0000245 0.556 0.00670
Bloemfontein 0.753 0.0000993 0.500 0.0147
Table S5: Summary table of the Spearman rank correlation coefficient and associated p-values between
rate estimates using the our integrated method and the ODE method.
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Figure S2: Comparing time to escape/reversion as estimated from the Bloemfontein data
using the integrated method to estimates generated using all available African data and
the naive approach. Spearman rank correlation coefficients (ρ) with associated p-values are dis-
played. Negatopes are highlighted in red for time to escape. Numbers after the abbreviation of each
epitope refers to the ordering in Tables S2 - S4, as some epitopes have more than one escape mutation
and/or associated restricting HLA. y = x is shown in solid grey.
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Figure S3: Comparing time to escape/reversion as estimated from the SSITT/HOMER
data using the integrated method to estimates generated using all available African data
and the naive approach. In Figures S3A - S3B SSITT and HOMER MAP estimates are plotted
against a naive estimate of the escape rate. Spearman rank correlation coefficients (ρ) with associated
p-values are displayed. Negatopes are highlighted in red. Numbers after the epitope abbreviation
refer to the ordering in Tables S2 - S4, as some epitopes have more than one escape mutation and/or
associated restricting HLA. We also plot y = x in solid grey where estimates are on the same timescale.
Dotted grey lines represent an estimate of y = x after a change of timescale assuming the Swiss and
Canadian epidemics are expanding at roughly the same rate.
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Figure S4: Comparing time to reversion as estimated from the SSITT/HOMER data to
estimates of time to reversion using the large African dataset and the naive approach. In
Figures S4A - S4B SSITT and HOMER MAP estimates are plotted against a naive African estimate
of the reversion rate. Spearman rank correlation coefficients (ρ) with associated p-values are displayed.
Numbers after the abbreviation of each epitope refers to the ordering in Tables S2 - S4, as some epitopes
have more than one escape mutation and/or associated restricting HLA. y = x is plotted in solid grey
where estimates are on the same timescale. Dotted grey lines represent an estimate of y = x after a
change of timescale assuming the Swiss and Canadian epidemics are expanding at roughly the same
rate.
Escape Reversion
Study ρ p ρ p
SSITT 0.765 0.000175 0.114 0.331
HOMER 0.711 0.000963 0.466 0.0298
Bloemfontein 0.861 0.00000112 0.341 0.0768
Table S6: Summary table of the Spearman rank correlation coefficient and associated p-values between
escape and reversion rate estimates using the ODE model applied to the large African dataset, and
the SSITT, HOMER and Bloemfontein datasets.
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Figure S5: Scatter-plots of time to escape and reversion estimates against in vitro viral
replicative capacity: Bloemfontein. Replicative capacity plotted against the MAP estimates of
time to escape is shown in Figure S5A, and the MAP estimates of time to reversion in Figure S5B.
Epitopes are labelled by the first three amino acids. Numbers after the abbreviation of each epitope
refers to the ordering in Tables S2 - S4, as some epitopes have more than one escape mutation and/or
associated restricting HLA. Spearman rank correlation coefficients; ρ, with associated p-values are
displayed on each plot.
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Figure S6: Scatter-plots of estimates of time to escape and reversion estimated from all
African data using naive ODE approach against in vitro replicative capacity. Figure S6A
shows a scatter-plot of the respective escape rate estimates. Figure S6B shows the corresponding plot
for reversion rate estimates. Numbers after abbreviation of each epitope refers to the ordering in
Tables S2 - S4, as some epitopes have more than one escape mutation and/or associated restricting
HLA. Spearman rank correlation coefficients with associated p-values are shown.
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Figure S7: Sequence divergence by Hamming distance. We determine the Hamming distance
between each pair of sequences in SSITT, HOMER and Bloemfontein for nucleotide and amino acid
sequences. We then scale by sequence length to obtain a measure of sequence divergence. Nucleotide
sequence divergence is shown above the leading diagonal, and amino acid sequence divergence is plotted
below the leading diagonal. Black lines distinguish the SSITT, HOMER, Bloemfontein cohorts. The
leading diagonal is shown in blue.
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SSITT
HOMER
Bloemfontein
Figure S8: Neighbour joining tree. We show a neighbour joining tree obtained using the K81 [68]
model applied to the largest region of gag over which < 10% sequences contained a gap or an unknown
nucleotide in the sequence alignment. Terminal branches are coloured by cohort according to the
legend.
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